OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Delayed Deutsche Boerse AG 12:35:50 29/05/2024 am IST | ||
| 6.55 EUR | -5.76% |
|
| Current month | +5.95% | ||
| 1 month | +4.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 29/24/29 | 6.55 | -5.76% |
| 27/24/27 | 6.95 | +0.72% |
| 24/24/24 | 6.9 | -0.29% |
| 23/24/23 | 6.92 | +0.87% |
| 22/24/22 | 6.86 | -2.28% |
Delayed Quote Deutsche Boerse AG
Last update May 29, 2024 at 12:35 am IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD8ULB |
| ISIN | DE000SD8ULB0 |
| Date issued | 03/03/2021 |
| Strike | 6,410 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.45 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.16 € |
|---|---|
| Lowest since issue | 1.39 € |
| Spread | 0.08 € |
| Spread % | 1.21% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
156.7
USD
Average target price
170.1
USD
Spread / Average Target
+8.55%
- Stock Market
- Certificates
- Certificat
